Contineum Stock Price Drops 9.9% Following Failure of Mid-term Trials for Depression Drug Collaborated with Johnson & Johnson
2026-09-16 01:19:49
According to CoinMeta, as reported by Reuters, the stock price of Contineum fell by 9.9% due to the failure of a depression drug in collaboration with Johnson & Johnson during the mid-stage trials.
Source:Internet
This content is for market information only and does not constitute investment advice.
Follow CoinMeta official accounts to stay updated

Hot Articles
Refresh

What Is CASHCAT Coin? Why It Leads On-Chain Despite 26% Weekly Drop
12h ago

Top 10 Crypto Trading Apps Sept 2026: Ranking & Review
09-14 17:24

Bitcoin Trading Platforms 2026: Top 3 Exchanges Compared
09-11 18:09

Privacy Coin Sector Outlook Sept 2026: 4 Dark Horses
09-10 18:34

S&P 500 Top 5 Companies: The Leaders Explained at a Glance
09-09 17:57



